Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Indian J Gastroenterol ; 43(1): 48-63, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38308773

RESUMO

Crohn's disease (CD), a chronic inflammatory bowel disorder, manifests in various phenotypes, with fistulizing perianal CD (CD-PAF) being one of its most severe phenotypes. Characterized by fistula formation and abscesses, CD-PAF impacts 17% to 34% of all CD cases and with a significantly deleterious impact on patient's quality of life, while increasing the risk for anorectal cancers. The pathogenesis involves a complex interplay of genetic, immunological and environmental factors, with cytokines such as tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta (TGF-ß) playing pivotal roles. Diagnostic protocols require a multi-disciplinary approach including colonoscopy, examination under anesthesia and magnetic resonance imaging. In terms of treatment, biologics alone often prove inadequate, making surgical interventions such as setons and fistula surgeries essential. Emerging therapies such as mesenchymal stem cells are under study. The South Asian context adds layers of complexity, including diagnostic ambiguities related to high tuberculosis prevalence, healthcare access limitations and cultural stigma toward perianal Crohn's disease and ostomy surgery. Effective management necessitates an integrated, multi-disciplinary approach, especially in resource-constrained settings. Despite advances, there remain significant gaps in understanding the disease's pathophysiology and a dearth of standardized outcome measures, underscoring the urgent need for comprehensive research.


Assuntos
Doença de Crohn , Fístula Retal , Humanos , Doença de Crohn/complicações , Doença de Crohn/diagnóstico , Doença de Crohn/terapia , Fístula Retal/diagnóstico , Fístula Retal/etiologia , Fístula Retal/terapia , Qualidade de Vida , Fator de Necrose Tumoral alfa , Citocinas , Resultado do Tratamento
2.
Indian J Gastroenterol ; 43(1): 244-253, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37823984

RESUMO

BACKGROUND: Post-traumatic stress (PTS) is the psycho-physiological response to a traumatic or life-threatening event and is implicated in inflammatory bowel disease (IBD). IBD-PTS is present in up to 30% of white, non-Hispanic patients. The rates of IBD in Asian populations are expanding, making the exploration of IBD-PTS in this population imperative. METHODS: Adult patients of South/Southeast (S/SE) Asian decent with IBD for more than 6 months were recruited online via social media and patient-support groups. Participants completed the post-traumatic stress disorder (PTSD) Checklist-5 (PCL-5), the United States National Institutes of Health's Patient-Reported Outcomes Measurement Information System (NIH-PROMIS) -43 profile and demographics. S/SE Asian participants were age and sex matched (1:2) with randomly selected white, non-Hispanic controls. Statistical analyses evaluated differences in IBD-PTS symptoms between groups, the relationship between disease severity and health-related quality of life (HRQoL) and predictors of IBD-PTS severity. RESULTS: Forty-seven per cent of the 51 S/SE Asian participants met the diagnostic cut-off for PTSD on the PCL-5 compared to 13.6% of 110 IBD controls. The mean global score on the PCL-5 was three times higher in S/SE Asians. Patients of S/SE Asian decent were over five times more likely to have PTSD due to their IBD experiences than controls, nearly doubling when controlling for disease activity. More severe IBD-PTS was present in S/SE Asian patients with active disease and those with extraintestinal manifestations. Higher global levels of IBD-PTS were associated with poorer HRQoL in S/SE Asians where increased hyperarousal from IBD-PTS predicted more sleep disturbance. CONCLUSIONS: S/SE Asian patients are five times more likely to experience IBD-PTS than their white, non-Hispanic counterparts. Several cultural factors lead to IBD-PTS in S/SE Asian patients that must be considered by IBD providers. Preventing, screening for and treating IBD-PTS in this population appears warranted.


Assuntos
Colite Ulcerativa , Doenças Inflamatórias Intestinais , Transtornos de Estresse Pós-Traumáticos , Adulto , Humanos , Povo Asiático , Estudos de Casos e Controles , Colite Ulcerativa/complicações , Doenças Inflamatórias Intestinais/complicações , Qualidade de Vida , Transtornos de Estresse Pós-Traumáticos/etiologia , Transtornos de Estresse Pós-Traumáticos/complicações , Estados Unidos/epidemiologia , Brancos
3.
Gastroenterol Clin North Am ; 51(4): 885-895, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36376002

RESUMO

The prevalence of inflammatory bowel disease (IBD) is increasing substantially in non-White races and ethnicities in the United States. As a part of promoting quality of life in patients with IBD, the optimization of food-related quality of life (FRQoL) is also indicated. It is known that the practices of food avoidance and restrictive eating are associated with a reduced FRQoL in IBD. Gaining insight into sociocultural influences on FRQoL will aid in the provision of culturally competent interventions to improve FRQoL in patients with IBD.


Assuntos
Doenças Inflamatórias Intestinais , Qualidade de Vida , Humanos , Estados Unidos , Doenças Inflamatórias Intestinais/terapia , Doenças Inflamatórias Intestinais/epidemiologia , Alimentos , Doença Crônica
6.
JAMA Pediatr ; 176(10): 1047, 2022 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-35939316

Assuntos
Demografia , Humanos
7.
Inflamm Bowel Dis ; 28(8): 1293-1295, 2022 08 01.
Artigo em Inglês | MEDLINE | ID: mdl-35078220

RESUMO

Historically, inflammatory bowel disease trials report high rates of White patients enrollment. To promote initiatives toward diversifying the enrolled population, we assessed the reporting of race and ethnicity of patients enrolled in pharmaceutical clinical trials for ulcerative colitis.


Assuntos
Colite Ulcerativa , Doença de Crohn , Ensaios Clínicos como Assunto , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Desenvolvimento de Medicamentos , Humanos , Grupos Minoritários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...